



Basic Details

Organisation Chain	National Institute of Biomedical Genomics (Department of Biotechnology) NIBMG-Administration and Finance NIBMG-Finance and Accounts		
Tender Reference Number	NIBMG/Gene Panel/2024-25/012		
Tender ID	2024_NIBMG_763254_1		
Tender Type	EOI	Form of contract	EOI
Tender Category	Goods	No. of Covers	1
Payment Mode	Not Applicable	Is Multi Currency Allowed For BOQ	No
Is Multi Currency Allowed For Fee	No		

Cover Details, No. Of Covers - 1

Cover No	Cover	Document Type	Description
1	Fee/PreQual/Technical/Finance	.pdf	EOI DOCUMENTS

Tender Fee Details, [Total Fee in ₹ * - 0.00]

Tender Fee in ₹	0.00		
Fee Payable To	NA	Fee Payable At	NA
Tender Fee Exemption Allowed	NA		

EMD Fee Details

EMD Amount in ₹	0.00	EMD Exemption Allowed	NA
EMD Fee Type	NA	EMD Percentage	NA
EMD Payable To	NA	EMD Payable At	NA

Work /Item(s)

Title	NIBMG/Gene Panel/2024-25/012				
Work Description	Expression of Interest for Joint development and Commercialization of Gene Panel/Diagnostic kit for Early Oral Cancer Detection				
Pre Qualification Details	AS PER EOI DOCUMENTS				
Tender Value in ₹	1	Product Category	Miscellaneous Goods	Sub category	AS PER EOI DOCUMENT
Contract Type	Tender	Bid Validity(Days)	90	Period Of Work(Days)	90
Location	NIBMG KALYANI	Pincode	741251	Pre Bid Meeting Place	NA
Pre Bid Meeting Address	NA	Pre Bid Meeting Date	NA	Bid Opening Place	NIBMG KALYANI

Critical Dates

Publish Date	08-Jul-2024 06:00 PM	Bid Opening Date	30-Jul-2024 04:30 PM
Document Download / Sale Start Date	09-Jul-2024 09:00 AM	Document Download / Sale End Date	29-Jul-2024 04:00 PM
Clarification Start Date	09-Jul-2024 09:00 AM	Clarification End Date	16-Jul-2024 02:00 PM
Bid Submission Start Date	09-Jul-2024 09:00 AM	Bid Submission End Date	29-Jul-2024 04:00 PM

Tender Documents

NIT Document	S.No	Document Name	Description	Document Size (in KB)	
	1	Tendernotice_1.pdf	EOI DOCUMENT	205.17	
Work Item Documents					
	S.No	Document Type	Document Name	Description	Document Size (in KB)
	1	Tender Documents	EOIDOCUMENTS.pdf	EOI DOCUMENT	205.17

<u>Tender Inviting Authority</u>	
Name	DIRECTOR
Address	NIBMG KALYANI
<u>Tender Creator Details</u>	
Created By	Sujit Halder
Designation	Jr. Mgt. Assistant
Created Date	08-Jul-2024 04:05 PM



NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS

(A premier Autonomous Institute of Dept. of Biotechnology, Ministry of Science & Technology, Govt. of India)

EOI DOCUMENT

EOI No. NIBMG/Gene Panel/2024-25/012

Date : 08-07-2024

**Expression of Interest for Joint development and Commercialization of Gene Panel/Diagnostic kit
for Early Oral Cancer Detection**

July'2024

CRITICAL DATE SHEET

EOI No. NIBMG/Gene Panel/2024-25/012

Date : 08-07-2024

Published Date	08-07-2024 [06:00 PM]
Bid Document Download / Sale Start Date	09-07-2024 [09:00 AM]
Clarification Start Date	09-07-2024 [09:00 AM]
Clarification End Date	16-07-2024 [02:00 PM]
Bid Submission Start Date	09-07-2024 [09:00 AM]
Bid Submission End Date	29-07-2024 [04:00PM]
Bid Opening Date	30-07-2024 [04:30PM]

Expression of Interest for Joint development and Commercialization of Gene Panel/Diagnostic kit for Early Oral Cancer Detection

BRIC- National Institute of Biomedical Genomics (NIBMG) is a BRIC Institute, under the aegis of the Department of Biotechnology, Ministry of Science and Technology, in the year 2009. BRIC-NIBMG is explicitly devoted to research, training, translation & service and capacity-building in biomedical genomics. Based on deep genomic data and knowledge obtained from analysis of over 500 patients, scientists at BRIC-NIBMG have devised a gene panel for early oral cancer detection. Expression of Interest (EOI) is invited on behalf of the Director, BRIC-NIBMG, Kalyani for joint development and commercialization of gene panel/diagnostic kit for early Oral cancer detection.

1) Definitions

“Product” means the gene panel/detection kit for early Oral cancer detection.

“Bidder” means any firm making a formal proposal for licensing, further development and commercialization of the product. The word when used after the award of the contract shall mean the licensee with whom BRIC- NIBMG signs the agreement

“Document” means any embodiment of any text or image or any other electronic documents as per IT Act 2000

EoI Document Number	EoI No. NIBMG/Gene Panel/2024-25/012
Date of Publication	Date: 08-07-2024
Last date of submission	Date: 29-07-2024

2) Scope of work:

Joint Development and commercialization of a gene panel/diagnostic kit which will be used for Genomics based detection of very early oral cancer precursor lesions. Partners are sought who can lead the product through

- The gene panel/diagnostic kit should exhibit exceptional sensitivity and specificity for the detection of early oral cancer lesions based on the genomics markers obtained from a large number (>500) of patient samples.
- It should be possible to use the proposed gene panel/diagnostic kit in a clinical setting (like laboratories/district hospitals).
- The proposed gene panel/diagnostic kit should have a fast turnaround time, do rapid analysis and reporting, thereby enabling prompt diagnosis and timely treatment decisions.
- It should be cost-effective and affordable and give unambiguous results.
- The proposed gene panel/diagnostic kit can use any state-of-the-art technologies (for example genomics platform (sequencing, multiplex PCR, qPCR) and/or CRISPR and/or 3D printing to detect single nucleotide changes in the target genes/gene products.

BRIC-NIBMG commits to the co-development of the proposed the proposed gene panel /diagnostic kit to refine and expand the capabilities of the proposed gene panel /diagnostic kit.

The Company shall have valid provisions to provide all necessary infrastructure/ material/ manpower required for product development/ validation/ scale-up either directly or otherwise. The Company shall

have provisions to undertake the scale-up as required, manufacturing and commercialization of the product, in a set milestone. The Company shall be responsible for obtaining all the regulatory approvals required for commercialization or starting from R&D for product development to its commercialization.

2) Pre-qualification criteria: The following preconditions must be fulfilled by the bidder and supported by documentary evidence. Claims without documentary evidence will not be considered.

Sl. No.	Pre-Qualification Criteria (PQC)	Supporting copy of documents required (All documents must be self- attested by the authorized person of the bidder)
General Criteria		
1	The bidder shall be a legal entity, registered as Institution/Company/ LLP/ Society/ partnership firm/ proprietorship firm under respective acts in India.	Registration of firm/ organization/Company Incorporation Certificate from Registrar of Companies (ROC) /Partnership deed etc. whichever is applicable
2	The bidder must be registered in India with taxation and other administrative authorities.	GST Registration or GST exemption certificate/ PAN Card
3	The bidder should have proven prior experience of development manufacturing and/or R&D with manufacturing during the last ten years, either in-house or through agreed collaboration and must have marketed same/similar products in the past with a good track record.	Research paper/Pamphlet / brochure of the product/DCGI License for existing product. Supporting documents for collaboration, if any.
4	The bidder has to be profitable and should not have incurred overall loss in past three (3) years. (Applicable on commercial firms/organizations only)	Certificate from the Chartered Accountant of the Organization/ Audited Balance sheets for last three financial years or Income Tax return.
5	The bidder should have good track record and currently not black-listed/ barred by any Central / State Government	Undertaking on the Letter Head of the bidder duly signed & stamped by Authorized Signatory (As per format in Annexure 1)
6	GMP/ quality certification (ISO or approved Indian certification) of manufacturing facility and GLP/ necessary certifications for R & D	Copies of Certificates
7	The bidder should have functional laboratory to carryout R&D for the product development	Undertaking on Bidder's Letter Head, duly signed and stamped by the Authorized Signatory (As per format in Annexure 2)

NOTE- The provisions related to Startups registered with DPIIT shall apply and if eligible for consideration, the relevant documents are to be submitted with the EOI

3) Evaluation of the EOI

Interested applicants may please send their EOI and supporting documents as specified in PQC in a sealed envelope to the following email address: eoiresearch@nibmg.ac.in

The subject should be “EOI for Technology Transfer/ Joint Development from (name of the bidder)”

- Bidder should include a concept note about planning and execution of the work. The note should also indicate the following:
 - (a) the approximate cost of making the prototype of the product
 - (b) the time frame required for the development of the gene panel
 - (c) the approximate cost of the product in market if launched
 - (d) the financial plan for development of the prototype
 - (e) the fees to be paid by bidder to BRIC-NIBMG for developing the prototype, if awarded the contract.
- All bids received within the last date specified in the advertisement for EOI will be screened and evaluated by BRIC-NIBMG.
- BRIC-NIBMG reserved the right to seek additional documentation or clarifications as and when required.
- Screening of EoIs shall be carried out as per Pre-Qualification criteria mentioned in the EoI document and based on verification of documents submitted. Shortlisted bidder(s) shall be called for further meetings and will be allowed to participate in the Global tender to be uploaded in the CPP portal.
- The proposal will be rejected if not properly stamped and signed or documents pertaining to the PQC are missing.
- Only the bidders who are qualified in the EOI will be allowed to take part in the normal tendering process via CPPP portal
- The decision of BRIC-NIBMG in evaluation of responses to the EOI will be final. BRIC-NIBMG reserves the right to reject any or all the EOI received or to close the process without assigning any reason.
- At the global tendering stage, if all the scientific evaluations are equal, NIBMG will enter into agreement with the bidder(s) who brings maximum financial benefit to the Institute.

Potential partners will be provided with non-exclusive license for commercialization and marketing of the gene-panel to enable wider public health benefits.

Annexure 1

Undertaking with regard to blacklisting
(To be submitted on Company's Letter Head)

To,
Director
BRIC-National Institute of Biomedical Genomics
P.O.: N.S.S.,
Kalyani 741251,
West-Bengal

Subject: Undertaking regarding Blacklisting / Non-Debarment.

Ref: NIBMG/Gene Panel/2024-25/012

Sir,

It is hereby confirmed and declared that M/s..... (Company Name) currently has not been blacklisted / debarred by any Government Department / Public Sector Undertaking / or any other company for which works/assignments/services have been executed / undertaken.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Place:

Seal:

Annexure 2

Undertaking with regard to laboratory facility
(To be submitted on Company's Letter Head)

To,
Director
BRIC-National Institute of Biomedical Genomics
P.O.: N.S.S.,
Kalyani 741251,
West-Bengal

Subject: Undertaking regarding Blacklisting / Non-Debarment.
Ref: NIBMG/Gene Panel/2024-25/012

Sir,

It is hereby confirmed and declared that M/s (Company Name) do have

- i. Adequate laboratory infrastructure (equipped laboratory facility; please specify the facilities) and
- ii. Adequate no. of experienced staff/skilled personnel to undertake manufacture/ research/ commercialization of gene panel/diagnostic kit for early oral cancer detection.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Place:

Seal:

DETAILS OF TECHNOLOGY

Technology: Gene panel/Diagnostic kit for early oral cancer detection

Potential Impact:

Oral cancer is a significant health concern, with high mortality rates among males in India and is consistently among the top 5 causes of death among cancer patients in India in the last 2 decades. The proposed gene panel/diagnostic kit has the potential to early detection of oral cancer by targeting dysplastic lesions. Healthcare providers will benefit from the proposed gene panel/diagnostic kit as it will enable early detection and intervention of oral cancer, leading to better patient outcomes and reduced healthcare costs.

The proposed gene panel/diagnostic kit will offer an innovative tool for large-scale oral cancer screening, facilitating unbiased diagnosis and efficient testing workflows to Clinical Laboratories and public health providers/hospitals: